Connect with us

Industry

Big Pharma veteran joins British cannabis firm

Avida Global has appointed Peter Donovan as global commercial director.

Published

on

Guernsey cannabis
Avida Global is a British producer of high-quality medicinal cannabis oils

British cannabis firm Avida Global has taken another significant step forward as it moves towards becoming a world-leading medical cannabis producer.

The producer of high-quality medicinal cannabis oils has announced the appointment of Peter Donovan as global commercial director.

Avida Global chief commercial officer, Peter Donovan

Avida Global, global commercial director, Peter Donovan

In this newly created role, Donovan will be responsible for forging commercial and partnership opportunities globally with an initial focus on the UK and Europe. He starts his new role on Monday 23 August and will report directly to David Kirby, CEO.

Donovan has had a long and established career in the Big Pharma industry. 

Most recently, he headed up Business Development at FIGR Brands Europe/Pyxus International where he was responsible for driving sales of CBD raw materials. 

Read more: UK firm aims to become world-leading medical cannabis producer

He has also held roles at British American Tobacco, where he headed up the company’s Healthcare and Vaping Channel, CBD start up, Always Pure Organics, Pharmexx UK (Celesio GMBH) and Omega Pharma/A Perrigo Company.

Speaking about the appointment, Donovan commented: “Avida Global is a company with integrity and transparency at its core; from the cultivation and production of its oils, to the people who work across all lines of the business, it’s a company that practices what it preaches.

“It’s an exciting time in the medical cannabis sector and I’m proud to be joining a company with such a great ethos and ambition.”

VIDEO: Behind the scenes with British cannabis firm Avida Global

David Kirby, chief executive officer at Avida Global said: “We are extremely pleased to welcome Peter to the Avida Global team. His Big Pharma experience and acute commercial acumen are key as we look to accelerate our partnerships and make our oils available to a wider audience for whom purity and consistency are key.”

 

Sarah Sinclair is an award-winning freelance journalist covering health, drug policy and social affairs. She is one of the few UK reporters specialising in medical cannabis policy and as the former editor of Cannabis Health has covered developments in the European cannabis sector extensively, with a focus on patients and consumers. She continues to report on cannabis-related health and policy for Forbes, Cannabis Health and Business of Cannabis and has written for The i Paper, Byline Times, The Lead, Positive News, Leafie & others. Sarah has an NCTJ accreditation and an MA in Journalism from the University of Sunderland and has completed additional specialist training through the Medical Cannabis Clinicians Society in the UK. She has spoken at leading industry events such as Cannabis Europa.

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2024 PP Intelligence Ltd.